Doripenem

Catalog No.S5531

For research use only.

Doripenem is a new parenteral carbapenem antibiotic with broad-spectrum activity against gram-negative and gram-positive pathogens.

Doripenem Chemical Structure

CAS No. 148016-81-3

Selleck's Doripenem has been cited by 1 Publication

Purity & Quality Control

Choose Selective Antibiotics Inhibitors

Biological Activity

Description Doripenem is a new parenteral carbapenem antibiotic with broad-spectrum activity against gram-negative and gram-positive pathogens.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 420.50
Formula

C15H24N4O6S2

CAS No. 148016-81-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1C2C(C(=O)N2C(=C1SC3CC(NC3)CNS(=O)(=O)N)C(=O)O)C(C)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01366651 Terminated Drug: Doripenem Meningitis Janssen Research & Development LLC March 2012 Phase 1
NCT01524302 Completed Drug: Ceftaroline|Drug: Levofloxacin Pneumonia Bacterial|Community-acquired Gary E. Stein Pharm.D.|Forest Laboratories|Michigan State University February 2012 Phase 4
NCT01467648 Completed Drug: Doripenem Ventilator-Associated Pneumonia Sutep Jaruratanasirikul|Prince of Songkla University October 2010 Phase 4
NCT01401010 Completed Drug: Doripenem|Drug: doripenem Febrile Neutropenia Gary E. Stein Pharm.D.|Michigan State University August 2010 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Doripenem | Doripenem ic50 | Doripenem price | Doripenem cost | Doripenem solubility dmso | Doripenem purchase | Doripenem manufacturer | Doripenem research buy | Doripenem order | Doripenem mouse | Doripenem chemical structure | Doripenem mw | Doripenem molecular weight | Doripenem datasheet | Doripenem supplier | Doripenem in vitro | Doripenem cell line | Doripenem concentration | Doripenem nmr